Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Agios Pharmaceuticals (AGIO) Shares Outstanding (Weighted Average): 2013-2025

Historic Shares Outstanding (Weighted Average) for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to $58.1 million.

  • Agios Pharmaceuticals' Shares Outstanding (Weighted Average) rose 2.12% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $58.1 million, marking a year-over-year increase of 2.12%. This contributed to the annual value of $57.0 million for FY2024, which is 2.04% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) is $58.1 million, which was up 0.32% from $57.9 million recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) registered a high of $69.9 million during Q1 2021, and its lowest value of $54.3 million during Q4 2021.
  • For the 3-year period, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) averaged around $56.6 million, with its median value being $56.8 million (2024).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Shares Outstanding (Weighted Average) declined by 21.88% in 2022, and later grew by 2.14% in 2024.
  • Quarterly analysis of 5 years shows Agios Pharmaceuticals' Shares Outstanding (Weighted Average) stood at $54.3 million in 2021, then grew by 1.17% to $54.9 million in 2022, then increased by 1.72% to $55.9 million in 2023, then climbed by 2.04% to $57.0 million in 2024, then climbed by 2.12% to $58.1 million in 2025.
  • Its last three reported values are $58.1 million in Q3 2025, $57.9 million for Q2 2025, and $57.3 million during Q1 2025.